Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEW YORK and VIENNA, Austria, Nov. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
-
Comprehensive review highlights potential of HOOKIPA’s versatile arenavirus platform as a new immunotherapy strategy to address critical unmet needs in cancerPre-clinical and clinical data showcase...
-
Clinical collaboration to assess HB-200 in combination with KEYTRUDA® (pembrolizumab) as first-line treatmentHOOKIPA poised to advance clinical development program with randomized Phase 2 study in...
-
NEW YORK and VIENNA, Austria, Sept. 07, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
-
Phase 1 HB-200 data recognized at premier oncology meetings, highlighting potential of novel arenaviral platform to deliver a new class of immunotherapeuticsHOOKIPA on track to report comprehensive...
-
HOOKIPA’s arenaviral platform technology demonstrated ability to modulate the tumor microenvironment and induce potent melanoma-specific T cell responsesA single, intra-tumoral injection of the...
-
NEW YORK and VIENNA, Austria, Aug. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
-
NEW YORK and VIENNA, Austria, June 10, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
-
Novel arenaviral therapeutic HB-200 generates outstanding tumor antigen-specific CD8+ T cell responses (average of 6 percent and up to 40 percent of T cell pool)To-date, HB-201 monotherapy has shown...
-
Data from first-in-human Phase 1 study of arenaviral therapeutics, including first data on HB-201/HB-202 alternating 2-vector therapy and expanded data on HB-201, to be featured as oral...